Pulmonary Hypertension - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 226 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pulmonary Hypertension - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pulmonary Hypertension - Pipeline Review, H1 2015', provides an overview of the Pulmonary Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pulmonary Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Pulmonary Hypertension Overview 9
Therapeutics Development 10
Pipeline Products for Pulmonary Hypertension - Overview 10
Pipeline Products for Pulmonary Hypertension - Comparative Analysis 11
Pulmonary Hypertension - Therapeutics under Development by Companies 12
Pulmonary Hypertension - Therapeutics under Investigation by Universities/Institutes 17
Pulmonary Hypertension - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Pulmonary Hypertension - Products under Development by Companies 21
Pulmonary Hypertension - Products under Investigation by Universities/Institutes 26
Pulmonary Hypertension - Companies Involved in Therapeutics Development 27
Actelion Ltd 27
APT Therapeutics, Inc. 28
Arena Pharmaceuticals, Inc. 29
Asahi Kasei Pharma Corp. 30
Ascendis Pharma A/S 31
Bayer AG 32
Bial - Portela & Ca, S.A. 33
Biolab Sanus Farmaceutica Ltda. 34
Cardioxyl Pharmaceuticals, Inc. 35
Carolus Therapeutics, Inc. 36
Celladon Corporation 37
Celsion Corporation 38
Corridor Pharmaceuticals Inc. 39
Cytokinetics, Inc. 40
Eli Lilly and Company 41
Gilead Sciences, Inc. 42
HanAll Biopharma Co., Ltd. 43
Hanmi Pharmaceuticals, Co. Ltd. 44
Ikaria Inc. 45
Insmed Incorporated 46
Ironwood Pharmaceuticals, Inc. 47
Lacer, S.A. 48
Longevity Biotech, Inc 49
LTT Bio-Pharma Co., Ltd. 50
Mast Therapeutics, Inc. 51
Mezzion Pharma Co. Ltd. 52
miRagen Therapeutics, Inc. 53
Nippon Shinyaku Co., Ltd. 54
Novartis AG 55
PharmaIN Corporation 56
PhaseBio Pharmaceuticals, Inc. 57
Pluristem Therapeutics Inc. 58
Proteo, Inc. 59
Reata Pharmaceuticals, Inc. 60
RegeneRx Biopharmaceuticals, Inc. 61
Sagene Pharmaceuticals, Inc. 62
Silence Therapeutics plc 63
Sinoxa Pharma GmbH 64
Suda Ltd 65
Therametrics holding AG 66
Toray Industries, Inc. 67
United Therapeutics Corporation 68
Vectura Group plc 69
Vicore Pharma AB 70
Pulmonary Hypertension - Therapeutics Assessment 71
Assessment by Monotherapy Products 71
Assessment by Combination Products 72
Assessment by Target 73
Assessment by Mechanism of Action 77
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 84
(allopurinol + apocynin) - Drug Profile 84
(chlorthalidone + valsartan) - Drug Profile 85
ACP-009 - Drug Profile 86
ambrisentan - Drug Profile 87
Antibody for Cancer and PAH - Drug Profile 89
Antibody for Pulmonary Arterial Hypertension - Drug Profile 90
APT-102 - Drug Profile 91
bardoxolone methyl - Drug Profile 93
BAY sGCact - Drug Profile 96
beraprost sodium nanoparticles SR - Drug Profile 97
beraprost sodium SR - Drug Profile 98
BIA-51058 - Drug Profile 100
BL-214 - Drug Profile 101
bosentan CR - Drug Profile 102
C-122 - Drug Profile 103
C-21 - Drug Profile 104
C-301 - Drug Profile 106
CT-2009 - Drug Profile 107
DasKloster-1000-01 - Drug Profile 108
Drug for Pulmonary Hypertension - Drug Profile 110
Drug for Pulmonary Hypertension - Drug Profile 111
Elafin - Drug Profile 112
esuberaprost sodium - Drug Profile 115
fasudil - Drug Profile 116
GS-4997 - Drug Profile 117
HGP-1207 - Drug Profile 118
IK-3001 - Drug Profile 119
imatinib mesylate - Drug Profile 120
IW-1973 - Drug Profile 122
LA-419 - Drug Profile 123
lisuride - Drug Profile 124
macitentan - Drug Profile 126
Mydicar - Drug Profile 129
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile 131
Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile 132
PB-1046 - Drug Profile 133
PB-1120 - Drug Profile 135
Peptide to Antagonize Urotensin-II Receptor for PAH - Drug Profile 136
PGC-VIP - Drug Profile 137
PK-10453 - Drug Profile 138
R-190 - Drug Profile 139
R-197 - Drug Profile 141
ralinepag - Drug Profile 142
RGN-352 - Drug Profile 143
riociguat - Drug Profile 145
RNAi Oligonucleotide to Inhibit miR-145 for PAH - Drug Profile 148
selegiline + PDE-5 Inhibitor - Drug Profile 149
selexipag - Drug Profile 150
Small Molecule for Pulmonary Arterial Hypertension - Drug Profile 152
Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia - Drug Profile 153
Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile 154
Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension - Drug Profile 156
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile 157
Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile 158
Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile 159
Small Molecules to Inhibit MetAP-II for Oncology, Immunology, Infectious Disease, Cardiovascular and Metabolic Disorders - Drug Profile 160
sodium nitrite - Drug Profile 161
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 163
SUD-004 - Drug Profile 165
Synthetic Peptide to Agonize VPAC2 for Pulmonary Arterial Hypertension - Drug Profile 166
Synthetic Peptide to Inhibit NADPH Oxidase for Pulmonary Hypertension - Drug Profile 167
tadalafil - Drug Profile 168
treprostinil diolamine - Drug Profile 170
TXA-127 - Drug Profile 171
udenafil - Drug Profile 173
VR-876 - Drug Profile 175
Pulmonary Hypertension - Recent Pipeline Updates 176
Pulmonary Hypertension - Dormant Projects 207
Pulmonary Hypertension - Discontinued Products 210
Pulmonary Hypertension - Product Development Milestones 211
Featured News & Press Releases 211
Appendix 220
Methodology 220
Coverage 220
Secondary Research 220
Primary Research 220
Expert Panel Validation 220
Contact Us 220
Disclaimer 221

List of Tables
Number of Products under Development for Pulmonary Hypertension, H1 2015 15
Number of Products under Development for Pulmonary Hypertension - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Development by Companies, H1 2015 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2015 22
Comparative Analysis by Late Stage Development, H1 2015 23
Comparative Analysis by Clinical Stage Development, H1 2015 24
Comparative Analysis by Early Stage Development, H1 2015 25
Products under Development by Companies, H1 2015 26
Products under Development by Companies, H1 2015 (Contd..1) 27
Products under Development by Companies, H1 2015 (Contd..2) 28
Products under Development by Companies, H1 2015 (Contd..3) 29
Products under Development by Companies, H1 2015 (Contd..4) 30
Products under Investigation by Universities/Institutes, H1 2015 31
Pulmonary Hypertension - Pipeline by Actelion Ltd, H1 2015 32
Pulmonary Hypertension - Pipeline by APT Therapeutics, Inc., H1 2015 33
Pulmonary Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 34
Pulmonary Hypertension - Pipeline by Asahi Kasei Pharma Corp., H1 2015 35
Pulmonary Hypertension - Pipeline by Ascendis Pharma A/S, H1 2015 36
Pulmonary Hypertension - Pipeline by Bayer AG, H1 2015 37
Pulmonary Hypertension - Pipeline by Bial - Portela & Ca, S.A., H1 2015 38
Pulmonary Hypertension - Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 39
Pulmonary Hypertension - Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2015 40
Pulmonary Hypertension - Pipeline by Carolus Therapeutics, Inc., H1 2015 41
Pulmonary Hypertension - Pipeline by Celladon Corporation, H1 2015 42
Pulmonary Hypertension - Pipeline by Celsion Corporation, H1 2015 43
Pulmonary Hypertension - Pipeline by Corridor Pharmaceuticals Inc., H1 2015 44
Pulmonary Hypertension - Pipeline by Cytokinetics, Inc., H1 2015 45
Pulmonary Hypertension - Pipeline by Eli Lilly and Company, H1 2015 46
Pulmonary Hypertension - Pipeline by Gilead Sciences, Inc., H1 2015 47
Pulmonary Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 48
Pulmonary Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 49
Pulmonary Hypertension - Pipeline by Ikaria Inc., H1 2015 50
Pulmonary Hypertension - Pipeline by Insmed Incorporated, H1 2015 51
Pulmonary Hypertension - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 52
Pulmonary Hypertension - Pipeline by Lacer, S.A., H1 2015 53
Pulmonary Hypertension - Pipeline by Longevity Biotech, Inc, H1 2015 54
Pulmonary Hypertension - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 55
Pulmonary Hypertension - Pipeline by Mast Therapeutics, Inc., H1 2015 56
Pulmonary Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H1 2015 57
Pulmonary Hypertension - Pipeline by miRagen Therapeutics, Inc., H1 2015 58
Pulmonary Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 59
Pulmonary Hypertension - Pipeline by Novartis AG, H1 2015 60
Pulmonary Hypertension - Pipeline by PharmaIN Corporation, H1 2015 61
Pulmonary Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 62
Pulmonary Hypertension - Pipeline by Pluristem Therapeutics Inc., H1 2015 63
Pulmonary Hypertension - Pipeline by Proteo, Inc., H1 2015 64
Pulmonary Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 65
Pulmonary Hypertension - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 66
Pulmonary Hypertension - Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 67
Pulmonary Hypertension - Pipeline by Silence Therapeutics plc, H1 2015 68
Pulmonary Hypertension - Pipeline by Sinoxa Pharma GmbH, H1 2015 69
Pulmonary Hypertension - Pipeline by Suda Ltd, H1 2015 70
Pulmonary Hypertension - Pipeline by Therametrics holding AG, H1 2015 71
Pulmonary Hypertension - Pipeline by Toray Industries, Inc., H1 2015 72
Pulmonary Hypertension - Pipeline by United Therapeutics Corporation, H1 2015 73
Pulmonary Hypertension - Pipeline by Vectura Group plc, H1 2015 74
Pulmonary Hypertension - Pipeline by Vicore Pharma AB, H1 2015 75
Assessment by Monotherapy Products, H1 2015 76
Assessment by Combination Products, H1 2015 77
Number of Products by Stage and Target, H1 2015 79
Number of Products by Stage and Mechanism of Action, H1 2015 83
Number of Products by Stage and Route of Administration, H1 2015 86
Number of Products by Stage and Molecule Type, H1 2015 88
Pulmonary Hypertension Therapeutics - Recent Pipeline Updates, H1 2015 181
Pulmonary Hypertension - Dormant Projects, H1 2015 212
Pulmonary Hypertension - Dormant Projects (Contd..1), H1 2015 213
Pulmonary Hypertension - Dormant Projects (Contd..2), H1 2015 214
Pulmonary Hypertension - Discontinued Products, H1 2015 215